Skip to content
Screener

Castle Biosciences CSTL Total Liabilities

Total Liabilities at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$9.91B+3.5%
Veracyte logo
VeracyteVCYT
$91.99M-23.6%
Lucid Diagnostics logo
Lucid DiagnosticsLUCD
$30.08M-21.2%
Myriad Genetics logo
Myriad GeneticsMYGN
$336.3M+11.7%
Personalis, Inc. logo
Personalis, Inc.PSNL
$70.63M+7.1%
NeoGenomics logo
NeoGenomicsNEO
$566.51M+4.9%

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$978.5M+76.1%
Enterprise value$951.46M+86.2%
P/S2.9×+1.3×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-031263
ASSETSMarch 31, 2026 / (unaudited)December 31, 2025
Noncurrent operating lease liabilities25,11625,217
Noncurrent finance lease liabilities288314
Deferred tax liability2,3252,335
Total liabilities86,389107,683
Commitments and Contingencies (Note 12)
Stockholders’ Equity
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock, $0.001 par value per share; 200,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 30,295,965 and 29,686,314 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively3030

Item 1. Financial Statements.

FAQ

What is Castle Biosciences's total liabilities?
Castle Biosciences (CSTL) reported total liabilities of $86.39M in Q1 2026.
How has Castle Biosciences's total liabilities changed year-over-year?
Castle Biosciences's total liabilities increased by 40.7% year-over-year, from $61.41M to $86.39M.
What is the long-term trend for Castle Biosciences's total liabilities?
Over 5 years (2020 to 2025), Castle Biosciences's total liabilities has grown at a 35.4% compound annual growth rate (CAGR), from $23.64M to $107.68M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Castle Biosciences's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude